Six Pharma Firms Busted in Drug Trafficking Network

Jalandhar : are at the center of a major Enforcement Directorate (ED) operation that has uncovered a large-scale inter-state drug trafficking network being run under the guise of pharmaceutical manufacturing. According to official sources, the ED has launched a thorough investigation into six pharma companies suspected of producing and distributing controlled substances under the cover of legal drug production. The probe intensified following intelligence inputs that these companies were misusing their drug licenses to illegally manufacture and distribute narcotics across various states including Punjab, Haryana, Delhi, Rajasthan, and Uttar Pradesh. The ED has conducted raids at over 22 locations linked to these companies including their registered offices, warehouses, supply chain points, and residential premises of directors and staff involved. During the raids, multiple incriminating documents, electronic records, and suspicious transaction data have been seized. These documents point toward a structured network involving fake billing, benami bank accounts, and covert transport operations. The ED has frozen several bank accounts associated with the accused companies and is scrutinizing their financial transactions for evidence of money laundering and tax evasion. Officials revealed that certain well-known pharma brands are also under the scanner and may face action in the coming weeks if links to the racket are established. This crackdown aligns with the central government’s zero-tolerance policy toward drug trafficking and organized crime. The agencies are collaborating with local police departments and the Narcotics Control Bureau (NCB) to ensure that no aspect of the illegal operation goes unchecked. Investigators believe that the accused exploited legal loopholes to smuggle banned substances under the cover of regular pharmaceutical logistics. The ED has stated that all those found guilty will be prosecuted under stringent provisions of the NDPS Act, PMLA, and other applicable laws. This revelation has sent shockwaves across the pharmaceutical industry and raised serious concerns about regulatory gaps that allow such criminal networks to thrive under the radar. Authorities have assured the public that the crackdown will continue and those exploiting the health sector for illegal gain will not be spared. Further developments are expected as forensic analysis of the seized evidence progresses.